MetaCap

iSpecimen (ISPC) vs OmniAb (OABI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OmniAb is the larger company by market cap ($679.7 million vs $2.6 million), about 257.3 times the size. OmniAb converts more of its revenue into profit, with a net margin of -347.0% versus -543.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ISPC-58.52%OABI+2.19%
+20%-21%-62%
Oct 7, 20261 yearNov 20, 2026
ISPC-59.62%OABI-2.71%
+10%-26%-63%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ISPC versus OABI key metrics
MetricISPCOABI
Share price$0.4563$4.66
Market cap$2.64M$679.71M
1-day change-13.58%-7.36%
YTD return—+151.89%
1-year return—+163.28%
5-year return—-53.40%
EPS (TTM)$-52.98$-0.34
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.93M$18.67M
Revenue growth (YoY)-79.24%-29.27%
Net income (latest FY)$-10.49M$-64.78M
Gross margin11.18%—
Operating margin-465.42%-369.49%
Net margin-543.68%-347.04%
52-week high$27.44$5.45
52-week low$0.432$1.35
Distance from 52-week high-98.34%-14.50%
Analyst consensus—none
Avg. price target upside—+78.76%
Average volume598.66K1.46M
Shares outstanding5.79M145.86M
Employees789
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OmniAb is about 257.3 times larger than iSpecimen by market value ($679.71M vs $2.64M).
  • OmniAb is more profitable, keeping -347.0 cents of every revenue dollar as net income versus -543.7 cents for iSpecimen.
  • OmniAb grew revenue faster in its latest fiscal year (-29.27% vs -79.24%).

About iSpecimen

ISPC stock →

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees

About OmniAb

OABI stock →

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees

ISPC vs OABI FAQ

Which is bigger, iSpecimen or OmniAb?

OmniAb (OABI) is larger, with a market capitalization of $679.71M compared with $2.64M for iSpecimen (ISPC).

Are iSpecimen and OmniAb in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons